← Leaderboards
James Kochenderfer
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteClinical TrialsChimeric Antigen ReceptorMalignant NeoplasmsAntigensCellsToxic EffectDesignCd19 GeneDisease RemissionLeukemia/LymphomaChimeric Antigen Receptor T CellsT Cell TherapyB-LymphocytesPublishingLymphomaB Lymphoid MalignancyProteinsResponseInfusion ProceduresPaperBloodCancer CellCellular Transduction
Grant awards (65)
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$693,831
ZIA · FY2025 · CA · contact PI
Adoptive T-cell Therapies Targeting Mutations in Hematologic Malignancies$693,831
ZIA · FY2025 · CA · contact PI
Development of CAR T cells targeting T-cell malignancies$693,831
ZIA · FY2025 · CA · contact PI
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies$555,064
ZIA · FY2025 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$138,766
ZIA · FY2025 · CA · contact PI
Development of CAR T cells targeting T-cell malignancies$971,478
ZIA · FY2024 · CA · contact PI
Adoptive T-cell Therapies Targeting Mutations in Hematologic Malignancies$809,564
ZIA · FY2024 · CA · contact PI
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies$647,651
ZIA · FY2024 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$647,651
ZIA · FY2024 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$161,912
ZIA · FY2024 · CA · contact PI
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies$936,552
ZIA · FY2023 · CA · contact PI
Development of CAR T cells targeting T-cell malignancies$624,367
ZIA · FY2023 · CA · contact PI
Adoptive T-cell Therapies Targeting Mutations in Hematologic Malignancies$624,367
ZIA · FY2023 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$624,367
ZIA · FY2023 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$156,091
ZIA · FY2023 · CA · contact PI
Development of fully-human anti-CD30 chimeric antigen receptors$156,091
ZIA · FY2023 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$1,387,598
ZIA · FY2022 · CA · contact PI
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies$1,110,078
ZIA · FY2022 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$138,759
ZIA · FY2022 · CA · contact PI
Development of fully-human anti-CD30 chimeric antigen receptors$138,759
ZIA · FY2022 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$1,482,788
ZIA · FY2021 · CA · contact PI
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies$1,037,952
ZIA · FY2021 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$296,558
ZIA · FY2021 · CA · contact PI
Development of fully-human anti-CD30 chimeric antigen receptors$148,279
ZIA · FY2021 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$1,251,559
ZIA · FY2020 · CA · contact PI
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies$876,092
ZIA · FY2020 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$250,312
ZIA · FY2020 · CA · contact PI
Development of fully-human anti-CD30 chimeric antigen receptors$125,155
ZIA · FY2020 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$877,892
ZIA · FY2019 · CA · contact PI
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies$667,197
ZIA · FY2019 · CA · contact PI
Development of fully-human anti-CD30 chimeric antigen receptors$175,579
ZIA · FY2019 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$35,116
ZIA · FY2019 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$673,197
ZIA · FY2018 · CA · contact PI
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies$511,631
ZIA · FY2018 · CA · contact PI
Development of fully-human anti-CD30 chimeric antigen receptors$134,640
ZIA · FY2018 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$26,928
ZIA · FY2018 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$472,700
ZIA · FY2017 · CA · contact PI
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies$359,253
ZIA · FY2017 · CA · contact PI
Development of fully-human anti-CD30 chimeric antigen receptors$94,540
ZIA · FY2017 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$18,908
ZIA · FY2017 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$367,151
ZIA · FY2016 · CA · contact PI
New Chimeric Antigen Receptors for Treating Hematologic Malignancies$367,151
ZIA · FY2016 · CA · contact PI
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$244,768
ZIA · FY2016 · CA · contact PI
Development of fully-human anti-CD30 chimeric antigen receptors$183,575
ZIA · FY2016 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$61,191
ZIA · FY2016 · CA · contact PI
Development of fully-human anti-CD30 chimeric antigen receptors$303,392
ZIA · FY2015 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$252,827
ZIA · FY2015 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$202,262
ZIA · FY2015 · CA · contact PI
New Chimeric Antigen Receptors for Treating Hematologic Malignancies$202,262
ZIA · FY2015 · CA · contact PI
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$50,565
ZIA · FY2015 · CA · contact PI
New Chimeric Antigen Receptors for Treating Hematologic Malignancies$600,576
ZIA · FY2014 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$450,431
ZIA · FY2014 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$300,287
ZIA · FY2014 · CA · contact PI
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$150,144
ZIA · FY2014 · CA · contact PI
New Chimeric Antigen Receptors for Treating Hematologic Malignancies$168,229
ZIA · FY2013 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$126,171
ZIA · FY2013 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$84,115
ZIA · FY2013 · CA · contact PI
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$42,057
ZIA · FY2013 · CA · contact PI
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma$150,681
ZIA · FY2012 · CA · contact PI
New Chimeric Antigen Receptors for Treating Hematologic Malignancies$150,681
ZIA · FY2012 · CA · contact PI
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$86,103
ZIA · FY2012 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$43,052
ZIA · FY2012 · CA · contact PI
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$156,999
ZIA · FY2011 · CA · contact PI
New Chimeric Antigen Receptors for Treating Hematologic Malignancies$156,999
ZIA · FY2011 · CA · contact PI
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor$78,500
ZIA · FY2011 · CA · contact PI